Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1649 | Interleukin assessment in semen Wiki | 0.20 |
drug513 | Brief Psychiatric Rating Scale Wiki | 0.20 |
drug2416 | Personal protective equipment from biological hazard Wiki | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3665 | after-each-case room disinfection Wiki | 0.20 |
drug411 | Bereavement Virtual Support Group Wiki | 0.20 |
drug1276 | Fibreoptic Endoscopic Evaluation of Swallowing (FEES) Wiki | 0.20 |
drug3616 | Woebot Substance Use Disorder Wiki | 0.20 |
drug3320 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.20 |
drug3663 | aerosol box Wiki | 0.20 |
drug2913 | SECRET questionnaire Wiki | 0.20 |
drug2857 | SARS-CoV 2 RNA PCR Urine Wiki | 0.20 |
drug840 | Connor-Davidson Resilience Scale 10 items (CD-RISC 10) Wiki | 0.20 |
drug1663 | Intervention App Wiki | 0.20 |
drug1235 | Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol Wiki | 0.20 |
drug1083 | Dysphagia Handicap Index (DHI) Wiki | 0.20 |
drug2719 | RESP301, a Nitric Oxide generating solution Wiki | 0.20 |
drug683 | Cannabis, Medical Wiki | 0.20 |
drug3655 | [68Ga]Ga-DOTA-(RGD)2 PET/CT Wiki | 0.20 |
drug2341 | PLACEBO GROUP Wiki | 0.20 |
drug3683 | autologous adipose-derived stem cells Wiki | 0.20 |
drug410 | Berberine Wiki | 0.20 |
drug2856 | SARS-CoV 2 RNA PCR Semen Wiki | 0.20 |
drug3552 | Videofluoroscopy Wiki | 0.20 |
drug1560 | IPSS questionnaire Wiki | 0.20 |
drug3667 | airway management during sedation or general anesthesia Wiki | 0.20 |
drug1672 | Interview by psychologists Wiki | 0.20 |
drug3615 | Withings ScanWatch Wiki | 0.20 |
drug1549 | IIEF-5 questionnaire Wiki | 0.20 |
drug3751 | daily room disinfection Wiki | 0.20 |
drug4059 | transparent sheet Wiki | 0.20 |
drug3668 | all treatment about COVID-2019 Wiki | 0.20 |
drug1913 | Male Sexual Health Questionnaire (MSHQ) Wiki | 0.20 |
drug1268 | Favipiravir + Standard of Care Wiki | 0.20 |
drug3681 | assessment of the sequelae after hospitalization for Sars-COV-2 Wiki | 0.20 |
drug2798 | Reporting of anosmia, ageusia and other clinical symptoms Wiki | 0.20 |
drug544 | CD24Fc Wiki | 0.20 |
drug992 | Depression, Anxiety and Stress Scale Wiki | 0.20 |
drug3586 | Voice Symptom Scale (VoiSS) Wiki | 0.20 |
drug2020 | MinnRAP Peer Support Program Wiki | 0.20 |
drug3276 | Tele-delivered psychological intervention Wiki | 0.20 |
drug2424 | Phone call Wiki | 0.20 |
drug1273 | Feeling Good Digital App Wiki | 0.20 |
drug445 | Biological: COVID-19 convalescent plasma Wiki | 0.20 |
drug549 | CHLORPROMAZINE (CPZ) Wiki | 0.20 |
drug439 | Biological sampling Wiki | 0.20 |
drug2997 | Semen Qualitative Analysis Wiki | 0.20 |
drug1602 | Impact of Event Scale-Revised Wiki | 0.20 |
drug2047 | Montmorrillonite Wiki | 0.20 |
drug3676 | anti-SARS-CoV-2 convalescent plasma Wiki | 0.20 |
drug357 | BCG GROUP Wiki | 0.20 |
drug1223 | Exposure to the SARS-CoV-2 and its consequences Wiki | 0.20 |
drug3684 | autopsy Wiki | 0.20 |
drug3403 | Training session adressing information and health literacy Wiki | 0.20 |
drug376 | BNT162b1 Wiki | 0.12 |
drug362 | BCG-Denmark Wiki | 0.12 |
drug3632 | Yoga Wiki | 0.12 |
drug2469 | Placebo Administration Wiki | 0.10 |
drug377 | BNT162b2 Wiki | 0.10 |
drug2564 | Povidone-Iodine Wiki | 0.10 |
drug3140 | Standard of Care (SOC) Wiki | 0.09 |
drug391 | Baricitinib Wiki | 0.07 |
drug2938 | Saline Wiki | 0.06 |
drug3138 | Standard of Care Wiki | 0.06 |
drug1472 | Hydroxychloroquine Wiki | 0.02 |
drug2448 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.35 |
D001523 | Mental Disorders NIH | 0.26 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
D040921 | Stress Disorders, Traumatic NIH | 0.20 |
D006685 | Hoarseness NIH | 0.20 |
D019964 | Mood Disorders NIH | 0.20 |
D013001 | Somatoform Disorders NIH | 0.20 |
D000067877 | Autism Spectrum Disorder NIH | 0.20 |
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.20 |
D000066553 | Problem Behavior NIH | 0.20 |
D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.20 |
D009069 | Movement Disorders NIH | 0.20 |
D001997 | Bronchopulmonary Dysplasia NIH | 0.20 |
D008595 | Menorrhagia NIH | 0.20 |
D006948 | Hyperkinesis NIH | 0.20 |
D006929 | Hyperaldosteronism NIH | 0.20 |
D014552 | Urinary Tract Infections NIH | 0.20 |
D054559 | Hyperphosphatemia NIH | 0.20 |
D055154 | Dysphonia NIH | 0.20 |
D004314 | Down Syndrome NIH | 0.20 |
D011602 | Psychophysiologic Disorders NIH | 0.20 |
D003291 | Conversion Disorder NIH | 0.20 |
D005879 | Tourette Syndrome NIH | 0.20 |
D014832 | Voice Disorders NIH | 0.20 |
D003424 | Crohn Disease NIH | 0.20 |
D000309 | Adrenal Insufficiency NIH | 0.20 |
D007008 | Hypokalemia NIH | 0.20 |
D010300 | Parkinsonian NIH | 0.16 |
D001008 | Anxiety Disorders NIH | 0.16 |
D005356 | Fibromyalgia NIH | 0.14 |
D000070642 | Brain Injuries, Traumatic NIH | 0.14 |
D015775 | Fractures, Stress NIH | 0.14 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.14 |
D012640 | Seizures NIH | 0.14 |
D002659 | Child Development Disorders, Pervasive NIH | 0.14 |
D016472 | Motor Neuron Disease NIH | 0.14 |
D000068376 | Compassion Fatigue NIH | 0.14 |
D000067073 | Psychological Trauma NIH | 0.14 |
D006526 | Hepatitis C NIH | 0.14 |
D001714 | Bipolar Disorder NIH | 0.14 |
D003680 | Deglutition Disorders NIH | 0.12 |
D001321 | Autistic Disorder NIH | 0.12 |
D006470 | Hemorrhage NIH | 0.12 |
D013651 | Taste Disorders NIH | 0.12 |
D000437 | Alcoholism NIH | 0.12 |
D019966 | Substance-Related Disorders NIH | 0.10 |
D000755 | Anemia, Sickle Cell NIH | 0.10 |
D000857 | Olfaction Disorders NIH | 0.09 |
D001930 | Brain Injuries, NIH | 0.09 |
D001927 | Brain Diseases NIH | 0.09 |
D007153 | Immunologic Deficiency Syndromes NIH | 0.08 |
D009461 | Neurologic Manifestations NIH | 0.08 |
D009103 | Multiple Sclerosis NIH | 0.08 |
D015212 | Inflammatory Bowel Diseases NIH | 0.08 |
D013315 | Stress, Psychological NIH | 0.07 |
D012598 | Scoliosi NIH | 0.07 |
D007238 | Infarction NIH | 0.07 |
D059350 | Chronic Pain NIH | 0.07 |
D009203 | Myocardial Ischemia NIH | 0.06 |
D020521 | Stroke NIH | 0.05 |
D020141 | Hemostatic Disorders NIH | 0.05 |
D001778 | Blood Coagulation Disorders NIH | 0.05 |
D006973 | Hypertension NIH | 0.05 |
D003866 | Depressive Disorder NIH | 0.04 |
D013577 | Syndrome NIH | 0.04 |
D014947 | Wounds and Injuries NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D003141 | Communicable Diseases NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
D007239 | Infection NIH | 0.03 |
D016638 | Critical Illness NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.35 |
HP:0000729 | Autistic behavior HPO | 0.23 |
HP:0002905 | Hyperphosphatemia HPO | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002900 | Hypokalemia HPO | 0.20 |
HP:0000846 | Adrenal insufficiency HPO | 0.20 |
HP:0002487 | Hyperkinetic movements HPO | 0.20 |
HP:0001618 | Dysphonia HPO | 0.20 |
HP:0001621 | Weak voice HPO | 0.20 |
HP:0000132 | Menorrhagia HPO | 0.20 |
HP:0000708 | Behavioral abnormality HPO | 0.20 |
HP:0000859 | Hyperaldosteronism HPO | 0.20 |
HP:0100280 | Crohn's disease HPO | 0.20 |
HP:0001609 | Hoarse voice HPO | 0.20 |
HP:0100022 | Abnormality of movement HPO | 0.20 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.14 |
HP:0000717 | Autism HPO | 0.14 |
HP:0100754 | Mania HPO | 0.14 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.14 |
HP:0002015 | Dysphagia HPO | 0.12 |
HP:0001250 | Seizure HPO | 0.12 |
HP:0000458 | Anosmia HPO | 0.09 |
HP:0001298 | Encephalopathy HPO | 0.09 |
HP:0002721 | Immunodeficiency HPO | 0.08 |
HP:0002037 | Inflammation of the large intestine HPO | 0.08 |
HP:0012532 | Chronic pain HPO | 0.07 |
HP:0001658 | Myocardial infarction HPO | 0.06 |
HP:0001297 | Stroke HPO | 0.05 |
HP:0001928 | Abnormality of coagulation HPO | 0.05 |
HP:0000822 | Hypertension HPO | 0.05 |
HP:0000716 | Depressivity HPO | 0.04 |
Navigate: Correlations HPO
There are 25 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsThe study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Background: The COVID-19 outbreak has caused many changes to people s normal social patterns. The respiratory illness has been the major focus of public health efforts. But most experts also agree that government and public health mandates to slow the spread of the illness, such as social distancing, have a significant effect on people s mental health. Environmental stressors, such as constraints on activities, social contact, and access to resources, take a toll. Researchers want to learn how stressors related to COVID-19 affect mental health over time. Objective: To learn the relationship between stressors related to COVID-19 and self-rated measures of mental health symptoms and distress among a range of people. Eligibility: English-speaking adults ages 18 and older Design: This study will be conducted online. Participants will give their first and last name and email address. They will indicate if they have ever been in an NIH research study. They will get a username and password. Every 2 weeks for up to 6 months, participants will complete online study surveys. They will get email reminders. Some surveys will be repeated. At the end of the study, they will complete a set of end-of-study surveys. The surveys will ask about the following: Age, sex, race, and other sociodemographic data Mental and medical illness history and treatment Family medical history Mobility, self-care, and life activities Behaviors related to alcohol and substance use disorder Mental illness symptoms Psychological distress Stressors caused by the COVID-19 pandemic. Participants will get links to mental health resources, such as hotlines. They will also get guidance on steps to take to seek care or support. Study website: nimhcovidstudy.ctss.nih.gov
Description: Thoughts and feelings about mental health impact of COVID-19
Measure: NIMH COVID Study survey - adult responses Time: Biweekly online responsesDescription: Ratings on measures of mental health symptoms and distress
Measure: DSM XC and KS survey Time: Biweekly online self reportSince December 2019 the world has been shaken with an enormous global threat: the Covid-19 pandemic. This new kind of coronavirus is generating an unprecedented impact both on the general population and on the healthcare systems in most countries. Health services are trying to expand their capacity to respond to the pandemic, taking actions such as increasing the number of beds; acquiring necessary equipment to provide intensive therapy (ventilators), and calling retired health professionals and health students so they can assist the overwhelmed health care workforce. Unfortunately, these organizational changes at health facilities, along with the fears and concerns of becoming ill with the virus or infecting their families, put an enormous emotional burden on workers in health services which may lead to negative outcomes on mental health in this population. Recent cross-sectional studies in China indicate that health service workers exposed to people with Covid-19 reported higher rates of depressive and anxious symptoms. This negative impact on mental health among health workers in China has also been informally reported in other countries where the Covid-19 pandemic has been devastating in its effects (such as Spain and Italy), as well as in countries where the pandemic is becoming a growing public health problem. This is particularly relevant in regions with fewer resources (Latin America, North Africa), where there are limited means and the response from the health system is usually insufficient. Moreover, it is necessary to study these negative effects longitudinally considering that some effects will appear over time (post-traumatic stress). Accordingly, this prospective (0, 3, 6 and 12 months), multisite cohort study aims to describe, examine, and evaluate the impact of the Covid-19 pandemic on mental health and social factors among workers at health services from Latin America and the Caribbean, Europe and neighboring countries, the Middle East and North Africa, as well as Sub-Saharan Africa and Asia. Additionally, a team from the United States of America will also participate in this collaborative effort providing expertise on psychiatric epidemiology and supporting coordination across countries.
Description: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: 12 monthsDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: BaselineDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: 3 monthsDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: 6 monthsDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: 12 monthsDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: BaselineDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: 3 monthsDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: 6 monthsDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: 12 monthsDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: BaselineDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: 3 monthsDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: 6 monthsDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: 12 monthsDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: BaselineDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: 3 monthsDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: 6 monthsDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: 12 monthsDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: BaselineDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: 3 monthsDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: 6 monthsDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: 12 monthsDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: BaselineDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: 3 monthsDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: 6 monthsDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: 12 monthsDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: BaselineDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: 3 monthsDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: 6 monthsDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: 12 monthsDescription: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: BaselineDescription: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: 3 monthsDescription: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: 6 monthsCORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.
Given the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with psychiatric disorders and suspected of infection, hospitalized in a specific unit, at the psychiatric, somatic and pharmacological level.
Description: total severity score from the Impact of Event Scale-Revised (IES-R)
Measure: impact of the COVID-19 pandemic on psychiatric symptomatology Time: through study completion, an average of 2 yearCovid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.
Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19
Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 Time: 12 monthsDescription: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases
Measure: Progression of pre-existing neurological or psychiatric pathologies Time: 12 monthsThis study aims at evaluating the effectiveness of a mobile phone based intervention to prevent and manage mental health problems in healthcare workers at the frontline against COVID-19 in Spain. The intervention will consist in psychoeducation, delivered via a mobile App. Participants will be followed up during two weeks. The primary outcome will be symptomatology of depression, anxiety or stress.
Description: Depression, anxiety and stress scales (DASS21). Score range: 0 (worst outcome) to 21 (best outcome)
Measure: Depression, anxiety and stress Time: 2 weeksDescription: Davidson Trauma Scale (DTS). The DTS is a 17-item, Likert-scale, self-report instrument that assesses the 17 DSM-IV symptoms of PTSD. Both a frequency and a severity score can be determined. The DTS yields a frequency score (ranging from 0 to 68), severity score (ranging from 0 to 68), and total score (ranging from 0 to 136). Higher scores are indicative a worse outcome.
Measure: Post-traumatic stress syndrome Time: 2 weeksDescription: Insomnia Severity Index. Score range: 0 (best outcome) to 28 (worst outcome)
Measure: Insomnia Time: 2 weeksDescription: General Self-Efficacy Scale. Score range: 10 (worst outcome) to 40 (best outcome)
Measure: Self Efficacy Time: 2 weeksThe Professional Peer Resilience Initiative (PPRI) study is an observational study aimed at understanding how symptoms of traumatic stress and resilience evolve over time in the University of Minnesota (UMN) healthcare workforce during the coronavirus disease 2019 (COVID-19) pandemic. The study is being conducted concurrently with a UMN peer support program called the MinnRAP program and will remotely administer quality of life and mental health surveys to healthcare workers before they start the MinnRAP program and throughout their participation in the program.
Description: Professional Quality of Life Questionnaire (proQOL): min score of 10; max score of 50; higher scores mean worse outcome
Measure: Change in professional quality of life Time: Before peer support program, through study completion (an average of 7 months)Description: Stress Risk & Resilience Self-Index: min score 0; max score of 12; higher scores mean worse outcome
Measure: Change in mental health symptoms and resilience markers Time: Before peer support program, through study completion (an average of 7 months)Participants are healthcare workers and adult outpatients referred in a COVID-19 screening center. Patients-reported symptoms are collected, then participants underwent a simple olfactory test (CODA for Clinical Olfactory Dysfunction Assessment), prior to swabbing for SARS-CoV-2 diagnosis (RT-PCR). We aimed to evaluate the prevalence of smell and taste disorders, and to calculate the diagnostic value of patient-reported and clinically verified smell disorders in persons with suspected COVID-19.
Description: Diagnostic values of anosmia and ageusia for COVID-19 with questionnaire
Measure: Diagnostic values of anosmia and ageusia for COVID-19 Time: at inclusionDescription: Diagnostic values of CODA (Clinical Olfactory dysfunction Assessment) score for COVID-19 : Simple, fast, semi-objective olfactory test developed for epidemic context
Measure: Diagnostic values of CODA Time: at inclusionThe experience of a loved one's stay in a COVID-19 intensive care unit (ICU), either intubated or on respiratory support, forces family caregivers (hereafter 'caregivers') to face core existential fears, such as uncertainty and death. It also poses a serious threat to basic human needs for autonomy, competence, and relatedness, as family caregivers have no control over the illness, and limited prior competence in dealing with critical illness. COVID-19 likely aggravates this experience, as social distancing cuts caregivers off from visiting patients in the ICU, from using their usual social supportive network and the threat of infection extends to caregivers themselves, their children and family. Combined, these extreme circumstances put caregivers in emotional turmoil and in need of psychological support and assistance in managing difficult emotions. ICU caregivers are at risk of developing clinically relevant symptoms of anxiety or posttraumatic stress. During the patient's ICU stay, caregivers experience peri-traumatic distress, such as helplessness, grief, frustration and anger, that may predict later posttraumatic stress disorder (PTSD). Symptoms of anxiety and PTSD may last for months to years after the patient's discharge. Further, caregivers of patients who die in an ICU may be at greater risk of prolonged grief disorder. Supportive interventions may reduce psychological late effects in ICU caregivers, but the primary focus of the majority of interventions has been on communication or surrogate decision making. The CO-CarES study aims to develop and test the feasibility of a tele-delivered psychological intervention to enable caregivers of ICU patients with COVID-19 to better endure the overwhelming uncertainty and emotional strain and reduce the risk of posttraumatic stress and prolonged grief. The study hypothesizes that providing psychological intervention during and after the patients' hospitalization, can decrease peri-traumatic distress during ICU hospitalization and decrease risk of post-traumatic stress, anxiety, depression and perceived stress following discharge, as well as prolonged grief in bereavement. A secondary hypothesis is that changes in emotion regulation mediate effects of the intervention on long-term psychological outcomes.
Description: Rate of consent among informed eligible participants
Measure: Recruitment rate Time: At inclusionDescription: Rates of completion of intervention sessions among participants
Measure: Completion rate Time: During and post-intervention (1 month)Description: Symptoms of peri-traumatic distress, min. score 0, max score 24, higher score corresponds to worse distress
Measure: Peri-traumatic distress inventory (negative emotions) Time: Pre-post intervention (1 month after discharge/death)Description: Posttraumatic stress, min. score 6, max score 24, higher score corresponds to worse distress
Measure: Impact of Events Scale (6 item) Time: 1 month post interventionDescription: Posttraumatic stress, min. score 6, max score 24, higher score corresponds to worse distress
Measure: Impact of Events Scale (6 item) Time: 6 months post interventionDescription: Posttraumatic stress, min. score 6, max score 24, higher score corresponds to worse distress
Measure: Impact of Events Scale (6 item) Time: 12/13 months post interventionDescription: Prolonged Grief, scored according to diagnostic criteria for prolonged grief disorder
Measure: Prolonged Grief-13-scale Time: 6 and 13 monthsDescription: Symptoms of depression, min. score 8, max score 40, higher score corresponds to worse symptoms
Measure: PROMIS Depression (8 item scale) Time: Baseline to 1, 6, and 12/13 monthsDescription: Symptoms of anxiety, min. score 8, max score 40, higher score corresponds to worse symptoms
Measure: PROMIS Anxiety (8 item scale) Time: Baseline to 1, 6, and 12/13 monthsDescription: Perceived stress, min. score 0, max score 16, higher score corresponds to worse stress
Measure: Perceived Stress Scale (4 item) Time: Baseline to 1, 6, and 12/13 monthsDescription: Worry, min. score 3, max score 15, higher score corresponds to greater worry
Measure: Short Penn State Worry Questionnaire (3 items) Time: Baseline to 1, 6, and 12/13 monthsDescription: Brooding, min. score 5, max score 20, higher score corresponds to greater brooding/rumination
Measure: Brooding subscale of Ruminative Responses Scale Time: Baseline to 1, 6, and 12/13 monthsDescription: Intolerance of uncertainty, min score 2, max score 8, greater score indicates greater uncertainty intolerance
Measure: Intolerance of uncertainty Scale (2 item) Time: Baseline to 1, 6, and 12/13 monthsIn response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).
Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.
Measure: Interview of the parents : contextual data Time: BaselineDescription: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)
Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: BaselineDescription: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)
Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: 1 monthDescription: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)
Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: 3 monthsDescription: Data relating to disease and management of care. Experience of the referring caregiver.
Measure: Interview of the referring caregiver : data relating to disease and management of care Time: 3 monthsThis research will provide data on thermal condition of medical workers who use personal protective equipment from biological hazards. Aquired data will be used to define acceptable period of use for these protective costumes. This research will recruit 6 volunteers. During 6 hours each subject will perform their work using protective costume. Heart rate, skin and air temperature under costume and hygrometric data will be registered. Also there will be questionnaires for volunteers for subjective assessment of thermal and moisture sensations.
Description: DS1923-F5 Thermochron iButtons
Measure: Skin thermometry Time: 6 hoursDescription: DS1923-F5 Thermochron iButtons
Measure: Hygrometry under costume Time: 6 hoursDescription: A Polar H10 heart rate monitor (Polar Electro, Finland) will carry all items during the entire research
Measure: Heart rate Time: 6 hoursDescription: Meteoscop - M
Measure: Air thermometry Time: 6 hoursDescription: Meteoscop - M
Measure: Air hygrometry Time: 6 hoursThe aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.
This study is part of the current global emergency scenario due to infection with Coronavirus, SARS-CoV-2 as indicated by the international taxonomy. Study aim is to investigate the possibility of the presence of the virus within the seminal fluid and in the urine of infected patients, both during the acute phase and remotely. Current evidences show that Coronaviruses can be present inside the testicle and sperm in other species, such as in feline and avian models. In human beings, current researches have mixed results regarding the presence of SARSCoV-2 in urine, as several studies with a large sample found no traces of the same with Real-Time Reverse method Transcriptase - Polymerase Chain Reaction or with method of nucleic acid amplification. By contrast, in just over 6% of 58 patients with Real Time Polymerase Chain Reaction method have found the presence of SARS-CoV-2 in the urine, even at a distance from the last negative nasopharyngeal swab. Given the topicality of the problem, our study has the objective of specifically researching the presence and possible persistence over time of SARS-CoV-2 in seminal fluid and urine. A saliva sample will also be collected as a control. At the moment there are no studies in literature that tested this possibility. If confirmed, it would lead to find out another potential method of transmission, the sexual one, in asymptomatic patients or apparently no longer infectious with negative buffer. The rationale for our study is the evidence that in other species this type of transmission by coronaviruses is possible and that at present it has not been verified in mankind. The relevance of the study would be both in the case of a negative result, as the first study in its generally, both in the case of a positive result, due to the possibility of introducing new prevention measures in the long run.
Description: SARS-CoV 2 RNA PCR in semen
Measure: SARS-CoV 2 presence in semen Time: EnrollmentDescription: SARS-CoV 2 RNA PCR in urine
Measure: SARS-CoV 2 presence in urine Time: EnrollmentDescription: Interleukin quantitative analysis in Semen, to assess if past inflammation due to SARS-CoV 2 Infection was present
Measure: Inflammation in Semen Time: EnrollmentDescription: Spermiogram done following WHO guidelines and criteria
Measure: Semen quantitative and qualitative analysis Time: EnrollmentDescription: International Index of Erectile Function (IIEF-5) questionnaire administration. Score range from 0 to 25. Higher scores mean good erectile function
Measure: Erectile Function Time: EnrollmentDescription: SExual Chronicle REcording Table (SECRET) questionnaire administration Questionnaire helps to assess the sexual habits of individuals
Measure: Sexual Habits Time: EnrollmentDescription: International Prostate Symptom Score (IPSS) questionnaire administration Score range from 0 to 35. Higher scores mean worst urinary function
Measure: Urinary function Time: EnrollmentDescription: Male Sexual Health Questionnaire Short Form (MSHQ-SF) admnistration Higher scores mean better sexual and ejaculatory function
Measure: Sexual and Ejaculatory Function Time: EnrollmentStudies have shown that admission to hospital during a coronavirus epidemic is associated with increased levels of anxiety, depression and panic disorder. During the SARS-CoV-2 pandemic in North London the Royal Free Hospital admitted over 500 patients with Covid-19. As part of the standard of care, these patients are screened at 8 weeks post discharge for signs of anxiety and depression. The Feeling Good app is a NHS approved digital application which utilises applied relaxation, mindfulness based cognitive therapy and positive visualisation through audio tracks for the treatment of anxiety and depression. This is a naturalistic cohort study aimed to track the post illness psychological symptoms of those who have been admitted with Covid-19 to the Royal Free hospital up to 5-7 months after discharge. The study population is those who are exhibiting anxiety or depressive symptoms as measure by the PHQ-2 or TSQ questionnaires. All those with symptoms will be offered free access to a NHS approved app for anxiety and depression, and followed up for 3 months after recruitment to track changes to their symptoms.
Description: Generalised anxiety disorder score (GAD-7) scale. Score 0-21, with a higher score associated with greater anxiety symptoms. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. GAD-7 score at baseline will be controlled for.
Measure: Anxiety as measured by generalised anxiety disorder score (GAD-7) scale Time: Day 14Description: The Patient Health Questionnaire (PHQ-9) is a screening tool for the identification of depressive disorders, which has been validated for use in primary care. Each of the nine items in the questionnaire is based on the DSM diagnostic criteria for clinical depression. The PHQ-9 is scored out of 27 according to severity, where score of 5-9 indicates mild depression, 10-14 moderate, 15-19 moderately severe, and 20 or above severe depression.
Measure: Depression as measured by the patient health questionnaire 9 (PHQ-9) Time: 14 days and week 12Description: The Trauma screening questionnaire (TSQ) is a 10 point scale used to identify symptoms of post traumatic stress disorder (PTSD), with a score between 0 and 10, with a score of 6 or higher scored as positive.
Measure: Trauma as measured by Trauma screening questionnaire (TSQ) Time: 12 weeksDescription: Generalised anxiety disorder score (GAD-7) scale. Score 0-21, with a higher score associated with greater anxiety symptoms. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. GAD-7 score at baseline will be controlled for.
Measure: Anxiety as measured by generalised anxiety disorder score (GAD-7) scale Time: Week 12Description: Risk factors for psychological distress from admission with Covid-19 will be collected, these will include, age, gender, ethnicity, length of hospital stay, oxygen requirement, co-morbidites, years of education, smoking status, occupation.
Measure: Risk associated with distress Time: Baseline analysisDescription: Framework analysis. Qualitative feedback of patient experience. Semi structured interviews of a subset of patients will be performed to gain further insight into the patient experience. These will be analysed using a framework thematic analysis, to identify themes which will then be used to code the text.
Measure: Qualitative analysis Time: BaselineAs a result of the pandemic, hygiene and distancing rules must be followed in Health care/ rehabilitation clinics to ensure the safety of patients and staff. This has led to extensive changes in the therapy processes, including a reduction in group sizes and maintaining distances within the groups, resulting in a reduction in the range of therapies available to individuals, since the number of employees remains unchanged and cannot be increased at will and in the short term due to the lack of qualified staff. In order for the treatment/rehabilitation goals to be achieved nonetheless, new forms of implementation of therapy programs must be developed in addition to organizational adjustments. Digitalization can be a significant support in this respect. The majority of patients in psychosomatic rehabilitation/parkinson treatment possess smartphones, meaning that the necessary infrastructure for the utilization of digital offers is available and can be used to the greatest possible extent. The use of digital measures within the therapeutic services supports the independence of the patients, as they can use the digital offers independently and flexibly in their own time. How should Health care/rehabilitation services be designed in light of the SARS-CoV-2 pandemic and which services have the potential to buffer future crises: What general recommendations can be derived for the design of such services for routine care?
Description: Quantitative online questionnaire Survey using UniPark
Measure: Interest in digital interventions (attitudes, behavioral intentions, behavioral experiences) Time: T1 (prior/beginning of rehab/clinic stay); T2 (end of rehab/clinic stay approx. 5 weeks after T1)Description: Quantitative online questionnaire Survey using UniPark
Measure: Usability and effectiveness of digital interventions Time: T1 (prior/beginning of rehab/clinic stay); T2 (end of rehab/clinic stay approx. 5 weeks after T1)Description: Quantitative online questionnaire Survey using UniPark
Measure: Stressors and barriers due to Covid-19 Time: T1 (prior/beginning of rehab/clinic stay); T2 (end of rehab/clinic stay approx. 5 weeks after T1)Primary objective is to evaluate the feasibility of delivering an online early Eye Movement Desensitisation Reprocessing (EMDR) Recent Traumatic Events Protocol (R-TEP) to patients who have survived Covid-19 related critical illness, within the context of a randomised controlled trial (RCT). This will inform the design of a future RCT investigating the effectiveness of EMDR R-TEP in reducing psychological symptoms, for adult survivors of intensive care.
Description: Feasibility will be determined by the following measures: Able to recruit >30% of eligible patients approached Complete early EMDR intervention programme in 75% or more of trial participants randomised to intervention. Protocol adherence Assignment of causality of serious events will be assessed by the chief investigator. Events attributable to trial procedures will be reviewed by trial management board, study sponsor and the research ethics committee, in order to determine ongoing feasibility. Outcome measures completed in 75% or more of trial participants
Measure: Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints Time: 12 monthsDescription: The PTSD Checklist-Civilian Version (PCL-C) is a validated, standardised self-reporting questionnaire for PTSD comprising of 17 items that correspond to key PTSD symptoms
Measure: Post-Traumatic stress disorder Time: 6 months post-hospital dischargeDescription: Hospital Anxiety and Depression Scale (HADS) is a 14-item, self-reported measure with 7-items relating to symptoms of anxiety and 7-items relating to depression
Measure: Anxiety and depression Time: 6 monthsDescription: Montreal Cognitive Assessment (MoCA) is a validated tool, used to detect cogntive impairment
Measure: Cognitive function Time: 6 months post-hospital dischargeDescription: EQ5D -5L comprises five quality-of-life dimensions; mobility, self-care, usual activities, pain/discomfort andanxiety/depression.
Measure: Health Related Quality of Life Time: 6 months post-hospital dischargeDescription: WHODAS 2.0 is a generic assessment tool that produces standarised disability levels and profiles
Measure: Health and disability Time: 6 months post-hospital dischargeDescription: Wrist worn physical activity monitoring
Measure: Physical activity Time: 6 months post-hospital dischargeDescription: Patient generated subjective global assessment
Measure: Nutritional status Time: 6 months post-hospital dischargeThe purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Description: Range from 0-100 (no pain to worst pain imaginable)
Measure: Pain rating Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-27, higher scores indicate greater levels of depression
Measure: Patient Health Questionnaire-9 (PHQ-9) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-21, higher scores indicate greater levels of anxiety
Measure: General Anxiety Disorder-7 (GAD-7) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Range from 8 to 32, with higher values indicating higher satisfaction
Measure: Client Satisfaction Questionnaire (CSQ) Time: Post-treatment (8 weeks from baseline)This study is designed to investigate the acuity of olfactory dysfunction in COVID-19 positive patients in the United Kingdom. In particular defining severity with objective testing and determining if this has any predictive value on the outcome of the SARS CoV-2 infection. In addition, this study will strive to determine duration / natural history of olfactory dysfunction in these patients in respect to a positive SARS CoV-2 diagnosis. It should also demonstrate the impact of olfactory dysfunction on patient Quality of Life (QOL).
Description: I. Primary endpoint is olfactory function assessed using the UPSIT and classified as Anosmia; Mild, moderate, and severe microsomia. assessed at the time COVID-19 diagnosis (+1 week) or at the time of registration for in hospital patients
Measure: UPSIT scores Time: At time of diagnosis (+1 week ) post COVID 19 diagnosis or at time of recruitment into studyDescription: I. The changes in olfaction in patients with SARS CoV-2 infection over an initial 12 month period (at day 0, 1 month, 3 month, 6 month, 9 month and 12 month) using the UPSIT.
Measure: UPSIT scores Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 monthDescription: Quality of Life using the validated Questionnaire of Olfactory Disorders for English speakers (eQOD)
Measure: eQOD scores Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 monthDescription: Quality of Life using the validated SinoNasal Outcome Tool-22 (SNOT-22)
Measure: SNOT 22 scores Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 monthThe investigators thought that the confinement measure took in France could induce an increase in the post traumatic syndrome in the relative of patient hospitalized in ICU during this period indeed the restricted visit and the limited interaction with ICU team are documented risk factors for PTSD in this population. The investigators designed an intervention in order to prevent the effect of the confinement measures on PTSD in relatives named OLAF. In this research the investigators aimed to study the impact on this intervention on PTSD.
Description: To demonstrate the benefits of a comprehensive family approach (OLAF) on the incidence of PTSD observed in 2 close referents of a patient, 6 months after leaving the intensive care unit, in the context of confinement linked to the SARS pandemic- CoV2.
Measure: incidence of PTSD observed 6 months after patient's discharge from the intensive care unit Time: Month 6Description: The incidence of PTSD 6 months after patient's death in the intensive care unit
Measure: incidence of PTSD observed 6 months after patient's death in the intensive care unit Time: Month 6Description: The incidence of PTSD 3 months after the death or discharge from the intensive care unit
Measure: PTSD incidence at month 3 Time: Month 3Description: The incidence of PTSD 12 months after the death or discharge from the intensive care unit
Measure: PTSD incidence at month 12 Time: Month 12Description: The incidence of symptoms of anxiety and / or depression 3 months after death or discharge from the intensive care unit
Measure: Symptoms incidence at month 3 Time: Month 3Description: The incidence of symptoms of anxiety and / or depression 6 months after death or discharge from the intensive care unit
Measure: Symptoms incidence at month 6 Time: Month 6Description: The incidence of symptoms of anxiety and / or depression 12 months after death or discharge from the intensive care unit
Measure: Symptoms incidence at month 12 Time: Month 12Description: The incidence of persistent complicated grief 3 months after death in intensive care
Measure: incidence of persistent complicated grief at month 3 Time: Month 3Description: The incidence of persistent complicated grief 6 months after death in intensive care
Measure: incidence of persistent complicated grief at month 6 Time: Month 6Description: The incidence of persistent complicated grief 12 months after death in intensive care
Measure: incidence of persistent complicated grief at month 12 Time: Month 12Evaluating the smell and taste perceptions of patients hospitalized in the intensive care unit with suspicion of Coronavirus disease-19 diagnosis with a survey study
Description: incidence of taste and smell impairment in critically ill subjects
Measure: taste and smell impairment Time: up to 3 monthsThe COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.
Description: Daily number of admissions for acute cardio- and neurivascular conditions in France.
Measure: Daily number of admissions for acute cardio- and neurivascular conditions in France. Time: 1 dayDescription: Specific mortality rate.
Measure: Specific mortality rate. Time: 1 dayThe purpose of this study is to investigate the clinical correlates of the effects of the COVID-19 pandemic on patients with Functional movement disorder (FMD) and Parkinson s Disease (PD). Primary objectives: To evaluate the change in neurological symptoms domain of the survey between pre and post-COVID 19 in FMD and PD patients. Secondary objectives: - To evaluate the change in total score of the survey between pre and post COVID 19 in FMD and PD patients - To evaluate the change in other symptom domains of the survey between pre and post COVID 19 in FMD and PD patients. Domains include: Mood/Energy, sleep, symptoms of abnormal movements related or unrelated to primary disease, physical health and exercise related change Exploratory objectives: - To evaluate whether there is a modifying effect of disease group in the changes in total score or symptom domains - To evaluate whether there is a relationship between disease severity and changes in total score or symptom domains - To evaluate whether there is a correlation between changes across symptom domains - To evaluate whether there is a correlation in raw score across symptom domains within each period Research Methods: Data will be solely collected through the use of online instruments via CiSTAR as a designed questionnaire. Questionnaire items A questionnaire aimed at determining the effects of the COVID 19 pandemic and subsequent isolation on functional state of patients with FMD and PD. The questionnaire items include: Items investigating Mood/Energy before and after COVID 19 out break Items investigating Sleep habits before and after COVID 19 out break Items investigating Neurological symptoms before and after COVID 19 out break Items investigating daily functioning before and after COVID 19 out break Items investigating Exercise habits before and after COVID 19 out break No questionnaire items will be actionable , which are items that would identify an imminent risk for participant safety requiring urgent and immediate medical or psychiatric
Description: Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients.
Measure: Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients. Time: December 2021This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.
Description: Based on therapy outcome measures from FEES, VoiS
Measure: Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation). Time: t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months) Time: t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only. Time: t = day 5, day 10, day 14, day 21 - For in-patients only.Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with grade of ARDS Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with length of intubation Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation Time: t = day 0 and 9 monthsDescription: Questionnaire assessment: This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28
Measure: Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months. Time: t = day 0, 1 month and 9 months.Description: Questionnaire assessment: This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
Measure: Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months Time: t = day 0, 1 month and 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports